Home › Triple-Negative Breast Cancer › Kentucky
Triple-Negative Breast Cancer clinical trials in Kentucky
6 studies for Triple-Negative Breast Cancer are looking for participants at sites in Kentucky.
Cities in Kentucky
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0044), Edgewood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06393374Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Norton Cancer Institute, Louisville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Norton Healthcare, Inc., Louisville
- Mercy Health, Paducah
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- University of Kentucky-Lexington, Lexington
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT05846789Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Norton Cancer Institute /ID# 248903, Louisville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT05005403The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
- Baptist Health Clinical Research, Elizabethtown
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 27, 2022 · NCT05037825From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.